Skip to Content

Bending the Cost Curve in End-Stage Kidney Disease

Jul 12, 2022
2:00 pm EDT
Presented by Alio
Register Now Registration takes place at a third-party website.

About This Webinar

End Stage Kidney Disease (ESKD) is a rapidly growing healthcare and economic crisis that has failed to elicit a response of adequate proportion. Approximately 800,000 patients live with ESKD, and almost 150,000 new patients/year are diagnosed with ESKD. ESKD patients make up 1% of the Medicare population but account for 7.2% of Medicare spending, or $37B. These statistics demonstrate ESKD patient care is a costly challenge without commensurate evolution in policy, infrastructure, and innovation.

Intermittent monitoring is not enough. The lack of continuity of care results in $14B/year spent on preventable dialysis-related hospitalizations. Without continuous monitoring, care teams are unable to intervene in a timely manner, resulting in costly complications:

  • 40% of dialysis patients are hospitalized for fluid overload
  • 65% of dialysis hospitalizations are due to preventable vascular access and fluid management issues
  • Dialysis patients spend an average of 10 days/year in the ICU

ESKD hospitalization rates have increased over the last few years, standing in contrast to the broader Medicare population with decreased hospital discharge rates.

Health systems are able to continuously monitor dialysis patients in and out of the clinic through remote patient monitoring technology. Key requirements include ensuring the data is of clinical grade, insights are actionable, and technology is noninvasive, unintrusive and easy to use.

Rethinking the reimbursement and regulatory landscape to create greater access to innovation and encourage widespread public-private partnerships and value-based care will ultimately improve lives and health outcomes of ESKD patients while driving down costs.

The webinar will review and discuss:

  1. The scope and scale of the challenges facing the ESKD population
  2. The evolving reimbursement landscape - expand on paying for RPM, RTM and AI technologies
  3. Innovation in the medical technology sector that address the current challenges in the health care system – to prevent hospitalizations and improve patients’ lives
  4. Progress on eliminating barriers and creating the momentum necessary for scalable systemic change, such as the CURES Act and KidneyX

Attendees Will Learn About

  • How to navigate the latest policy (Medicare Advantage) changes that impact ESKD patients
  • Three meaningful shifts we can make to catalyze change for both the health system and patients alike
  • Reshaping the reimbursement landscape
  • Expanding pathways for patients to access and get coverage for innovative technologies
  • Fostering partnerships between the public and private sector


Eric D. Hargan

Founder and CEO

The Hargan Group

Mr. Hargan has 30 years of experience working for the public and private sectors and unique insight and experience working for the U.S. Government. He served as the Deputy Secretary of the Department of Health and Human Services (HHS) from 2017 to 2021, as well as Acting Secretary in 2017-2018. From 2003 to 2007, Mr. Hargan also served at HHS in a variety of capacities, including holding the…

Learn more about Eric D. Hargan

David Kuraguntla, DO

CEO and Co-Founder


Dave is the Co-Founder and CEO of Alio, a noninvasive remote monitoring company dedicated to improving the lives of those living with chronic kidney disease (CKD) and other chronic conditions. Dave received his master’s degree from Boston University and was a researcher at the National Institutes of Health. He then went to medical school on an Air Force scholarship. He received his medical…

Learn more about David Kuraguntla, DO